In the same study, both proved to cause the highest reduction of 2-HG levels in six different cancer cell lines with IDH mutation (HT1080 fibrosarcoma, SNU1079, and RBE cholangiocarcinoma, JJ012 chondrosarcoma, U87 glioblastoma, and THP-1 AML). This evidence concerns the gene IDH2 and acute myeloid leukemia.